Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AKAOQ OTCMKTS:ARGSQ OTCMKTS:RSPI OTCMKTS:SKVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKAOQAchaogen$0.03+0.8%$0.02$0.00▼$0.05$1.21M-0.81186,196 shs68,500 shsARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ARSPICortex Pharmaceuticals$0.00$0.00$0.00▼$0.00N/A0.54N/AN/ASKVISkinvisible$0.21$0.23$0.08▼$0.90$1.15M1.781,980 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKAOQAchaogen0.00%0.00%0.00%0.00%0.00%ARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%RSPICortex Pharmaceuticals0.00%0.00%0.00%+0.00%+1,700.00%SKVISkinvisible0.00%0.00%+10.91%+1.19%+20.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKAOQAchaogen$0.03+0.8%$0.02$0.00▼$0.05$1.21M-0.81186,196 shs68,500 shsARGSQArgos Therapeutics$0.05$0.05$0.02▼$0.25$572K2.4713,394 shsN/ARSPICortex Pharmaceuticals$0.00$0.00$0.00▼$0.00N/A0.54N/AN/ASKVISkinvisible$0.21$0.23$0.08▼$0.90$1.15M1.781,980 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKAOQAchaogen0.00%0.00%0.00%0.00%0.00%ARGSQArgos Therapeutics0.00%0.00%0.00%0.00%0.00%RSPICortex Pharmaceuticals0.00%0.00%0.00%+0.00%+1,700.00%SKVISkinvisible0.00%0.00%+10.91%+1.19%+20.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKAOQAchaogen 0.00N/AN/AN/AARGSQArgos Therapeutics 0.00N/AN/AN/ARSPICortex Pharmaceuticals 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKAOQAchaogen$8.73M0.14N/AN/AN/A∞ARGSQArgos Therapeutics$1.90M0.30N/AN/A($1.63) per share-0.03RSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/ASKVISkinvisible$20K57.40N/AN/A($1.90) per share-0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKAOQAchaogen-$186.51MN/AN/AN/AN/AN/AN/AN/AN/AARGSQArgos Therapeutics-$40.57MN/AN/AN/AN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/A-$0.02N/AN/AN/AN/AN/AN/AN/ASKVISkinvisible-$1.06M-$0.20N/AN/AN/A-5,245.00%N/A-800.79%N/ALatest AKAOQ, ARGSQ, SKVI, and RSPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SKVISkinvisibleN/A-$0.05N/A-$0.05N/AN/A3/31/2026Q4 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKAOQAchaogenN/AN/AN/AN/AN/AARGSQArgos TherapeuticsN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKAOQAchaogenN/AARGSQArgos TherapeuticsN/ARSPICortex PharmaceuticalsN/ASKVISkinvisibleN/AInsider OwnershipCompanyInsider OwnershipAKAOQAchaogen7.80%ARGSQArgos Therapeutics28.21%RSPICortex Pharmaceuticals50.03%SKVISkinvisible53.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKAOQAchaogen4248.21 millionN/ANot OptionableARGSQArgos Therapeutics12210.59 millionN/ANot OptionableRSPICortex Pharmaceuticals2949.46 million474.45 millionNot OptionableSKVISkinvisible25.40 million2.54 millionNot OptionableAKAOQ, ARGSQ, SKVI, and RSPI HeadlinesRecent News About These CompaniesSKINVISIBLE INC by Skinvisible, Inc. Insider Trading Activity | OTC:SKVI | BenzingaMay 17, 2026 | benzinga.comSkinvisible Inc.May 11, 2026 | marketwatch.comSkinvisible Stock Price HistoryOctober 9, 2025 | investing.comOvation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments ...September 19, 2025 | theglobeandmail.comOvation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent ProtectionSeptember 18, 2025 | accessnewswire.comASkinvisible Delays 10-K Filing Due to Compilation IssuesMarch 31, 2025 | tipranks.comSkinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | finanznachrichten.deSkinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | accessnewswire.comASkinvisible, Inc. (SKVI)November 16, 2024 | finance.yahoo.comSkinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation DevelopmentOctober 3, 2024 | accesswire.comAPromising Data on Transdermal Obesity Formulations Announced by SkinvisibleJuly 11, 2024 | accesswire.comASkinvisible Expands Obesity Patent Application for Transdermal DeliveryJune 24, 2024 | accesswire.comASkinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finanznachrichten.deSkinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finance.yahoo.comZHUD Zhuding International LimitedMay 15, 2024 | seekingalpha.comSkinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finanznachrichten.deSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finance.yahoo.comSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | accesswire.comAFree weights 362X germier than a toilet seatMay 26, 2023 | mensjournal.comMSkinvisible, Inc. (SKVI) Stock Historical Prices & Data - Yahoo FinanceMarch 2, 2023 | finance.yahoo.comMedia Sentiment Over TimeAKAOQ, ARGSQ, SKVI, and RSPI Company DescriptionsAchaogen OTCMKTS:AKAOQ$0.03 +0.00 (+0.81%) As of 06/18/2021Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.Argos Therapeutics OTCMKTS:ARGSQ$0.05 0.00 (0.00%) As of 10/10/2019Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.Cortex Pharmaceuticals OTCMKTS:RSPI$0.0018 0.00 (0.00%) As of 06/12/2026RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Skinvisible OTCMKTS:SKVI$0.21 0.00 (0.00%) As of 06/12/2026Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
